Abstract
In this survey the impact of the virtual screening concept is discussed in the field of drug discovery from nature. Confronted by a steadily increasing number of secondary metabolites and a growing number of molecular targets relevant in the therapy of human disorders, the huge amount of information needs to be handled. Virtual screening filtering experiments already showed great promise for dealing with large libraries of potential bioactive molecules. It can be utilized for browsing databases for molecules fitting either an established pharmacophore model or a three dimensional (3D) structure of a macromolecular target. However, for the discovery of natural lead candidates the application of this in silico tool has so far almost been neglected. There are several reasons for that. One concerns the scarce availability of natural product (NP) 3D databases in contrast to synthetic libraries; another reason is the problematic compatibility of NPs with modern robotized high throughput screening (HTS) technologies. Further arguments deal with the incalculable availability of pure natural compounds and their often too complex chemistry. Thus research in this field is time-consuming, highly complex, expensive and ineffective. Nevertheless, naturally derived compounds are among the most favorable source of drug candidates. A more rational and economic search for new lead structures from nature must therefore be a priority in order to overcome these problems.
Here we demonstrate some basic principles, requirements and limitations of virtual screening strategies and support their applicability in NP research with already performed studies. A sensible exploitation of the molecular diversity of secondary metabolites however asks for virtual screening concepts that are interfaced with well-established strategies from classical pharmacognosy that are used in an effort to maximize their efficacy in drug discovery. Such integrated virtual screening workflows are outlined here and shall help to motivate NP researchers to dare a step towards this powerful in silico tool.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
References
Brown D, Superti-Furga G (2003) Rediscovering the sweet spot in drug discovery. Drug Discov Today 8: 1067–1077
Drews J (2003) Strategic trends in the drug industry. Drug Discov Today 8: 411–420
Smith A (2002) Screening for drug discovery: the leading question. Nature 418: 453–459
Strohl WR (2000) The role of natural products in a modern drug discovery program. Drug Disc Today 5: 39
Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461–477
Harvey A (2000) Strategies for discovering drugs from previously unexplored natural products. Drug Disc Today 5: 294–300
Clardy J, Walsh C (2004) Lessons from natural molecules. Nature 432: 829–837
Jones WP, Chin YW, Kinghorn AD (2006) The role of pharmacognosy in modern medicine and pharmacy. CurrDrug Targets 7: 247–264
Dictionary of Natural Products provided by Chapman &Hall/CRC. Available at: http://www.crcpress.com/shopping_cart/products/product_detail.asp?sku=C9150 (accessed in January 2007)
Tulp M, Bohlin L (2005) Rediscovery of known natural compounds: Nuisance or goldmine? BioorgMed Chem 13: 5274–5282
Sitte P, Weiler EW, Kadereit JW, Bresinsky A, Körner C (2002) Strasburger — Lehrbuch der Botanik, 35. Auflage, Spektrum Akademischer Verlag, Heidelberg, Berlin, 339–351
Balandrin M (1993) Plant-derived natural products in drug discovery and development: an overview. Amer Chem Soc Symposium Series No 534: 2–12
Cragg GM, Newman DJ, Snader KM (1997) Natural products in drug discovery and development. J Nat Prod 60: 52–60
Henkel T, Brunne RM, Muller H, Reichel F (1999) Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew Chem Int Ed 38: 643–647
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar M, Doyle M, FitzHugh W et al (2001) Initial sequencing and analysis of the human genome. Nature 409: 860–921
Deisenhofer J, Smith JL (2001) Proteins. Curr Opin Struc Biol 11: 701–702
Maggio ET, Ramnarayan K (2001) Recent developments in computational proteomics. Drug Disc Today 6: 996–1004
Potterat O, Hamburger M (2006) Natural products in drug discovery — concepts and approaches for tracking bioactivity. Curr Org Chem 10: 899–920
Pottereat O (2006) Targeted approaches in natural product lead discovery. Chimia 60: 19–22
Morrell J (1996) Mining information from databases for drug discovery. Book Abstr 211th ACS National Meeting CINF-052
Gasteiger J, Teckentrup A, Terfloth L, Spycher S (2003) Neural networks as data mining tools in drug design. J Phys Org Chem 16: 232–245
Xu J, Hagler A (2002) Chemoinformatics and drug discovery. Molecules 7: 566–600
Alvarez AJ, Shoichet B (2005) Virtual screening in drug discovery. Taylor & Francis, CRC-Press, Boca Raton
Langer T, Hoffmann RD (2006) Pharmacophores and pharmacophore searches. In: Methods and principles in medicinal chemistry Vol. 32, Wiley-VCH, Weinheim
Manly CJ, Louise-May S, Hammer JD (2001) The impact of informatics and computational chemistry on synthesis and screening. Drug Discov Today 6: 1101–1110
Langer T, Hoffmann RD (2001) Virtual screening: an effective tool for lead structure discovery? CurrPharm Des 7: 509–527
Böhm HJ, Schneider G (2000) Virtual screening for bioactive molecules. Wiley, New York
Krovat EM, Steindl T, Langer T (2005) Recent advances in docking and scoring. Curr Comput-Aided Drug Des 1: 93–102
Abagyan R, Totrov M (2001) High-throughput docking for lead generation. Curr Opin Chem Biol 5: 375–382
Schneider G, Böhm HJ (2002) Virtual screening and fast automated docking methods. Drug Disc Today 7: 64–70
Shoichet BK, McGovern SL, Wei B, Irwin JJ (2002) Lead discovery using molecular docking. Curr Opin Chem Biol 6: 439–446
Stahl M, Rarey M (2001) Detailed analysis of scoring functions for virtual screening. J Med Chem 44: 1035–1042
Charifson PS, Corkery JJ, Murcko MA, Walters WP (1999) Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem 42: 5100–5109
Wang R, Wang S (2001) How does consensus scoring work for virtual library screening? An idealized computer experiment. J Chem Inf Comput Sci 41: 1422–1426
Liu B, Zhou J (2005) SARS-CoV protease inhibitors design using virtual screening method from natural products libraries. J Comp Chem 26: 484–490
Toney JH, Navas-Martin S, Weiss SR, Koeller A (2004) Sabadinine: a potential non-peptide anti-severe acute-respiratory-syndrome agent identified using structure-aided design. J Med Chem 47: 1079–1080
Cozza G, Bonvini P, Zorzi E, Poletto G, Pagano MA, Sarno S, Donella-Deana A, Zagotto G, Rosolen A, Pinna LA et al (2006) Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem 49: 2363–2366
Zhao L, Brinton RD (2005) Structure-based virtual screening for plant-based ERß-selective ligands as potential preventative therapy against age-related neuro-degenerative diseases. J Med Chem 48: 3463–3466
Liu H, Li Y, Song M, Tan X, Cheng F, Zheng S, Shen J, Luo X, Ji R, Yue J et al (2003) Structure-based discovery of potassium channel blockers from natural products virtual screening and electrophysiological assay testing. Chem Biol 10: 1103–1113
Langer T, Hoffmann RD (2006) Pharmacophore modelling: applications in drug discovery. Exp Opin Drug Discov 1: 261–267
Doman TN, McGovern SL, Witherbee BJ, Kasten TP, Kurumbail R, Stallings WC, Connolly DT, Shoichet BK (2002) Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem 45: 2213–2221
Samiulla DS, Vaidyanathan VV, Arun PC, Balan G, Blaze M, Bondre S, Chandrasekhar G, Gadakh A, Kumar R, Kharvi G et al (2005) Rational selection of structurally diverse natural product scaffolds with favorable ADME properties for drug discovery. Mol Divers 9: 131–139
Testa B (1984) Drugs? Drug research? Advances in drug research? Musings of a medicinal chemist. Adv Drug Res 13: 1–58
Smith DA, van de Waterbeemd H, Walker DK (2006) Pharmacokinetics and metabolism in drug design. 2nd Ed., Wiley-VCH, Weinheim
Avdeef A, Testa B (2002) Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques. Cell Mol Life Sci 59: 1681–1689
Feher M, Schmidt JM (2003) Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 43: 218–227
Stahura F, Godden JW, Ling X, Bajorath J (2002) Distinguishing between natural products and synthetic molecules by descriptor Shannon entropy analysis and binary QSAR calculations. J Chem Inf Comput Sci 40: 1254–1252
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23: 3–25
Congreve M, Murray CW, Blundell TL (2005) Structural biology and drug discovery. Drug Disc Today 10: 895–907
Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H, Shindyalov I, Bourne P (2000) The protein data bank. Nucleic Acids Res 28: 235–242
Wolber G, Langer T (2000) LigandScout: 3D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45: 160–169
Krovat EM, Frühwirth KH, Langer T (2005) Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa. J Chem Inf Model 45: 146–159
Rella M, Rushworth C, Guy JL, Turner AJ, Langer T, Jackson RM (2006) Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors. J Chem Inf Model 46: 708–716
Barreca ML, De Luca L, Iraci N, Rao A, Ferro S, Maga G, Chimirri A (2007) Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. J Chem Inf Model 47: 557–562
Schuster D, Laggner C, Steindl TM, Langer T (2006) Development and validation of an in silico P450 profiler based on pharmacophore models. Curr Drug Discov Technol 3: 1–48
Steindl TM, Schuster D, Laggner C, Langer T (2006) Parallel screening: a novel concept in pharmacophore modelling and virtual screening. J Chem Inf Model 46: 2146–2157
Steindl TM, Schuster D, Wolber G, Laggner C, Langer T (2007) High throughput structure-based pharmacophore modeling as a basis for successful parallel virtual screening. J Comput-aided Mol Des ASAP doi 10.1007/s10822-006-9066-y
Steindl TM, Schuster D, Laggner C, Chuang K, Hoffmann R, Langer T (2007) Parallel screening and activity profiling with HIV protease inhibitor pharmacophore models. J Chem Inf Model 47: 563–571
Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP, Wang R, Fang X, Guo R, Zhang M et al (2004) Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 47: 2430–2440
Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, Shi Y (2000) Structural basis of IAP recognition by Smac/DIABLO. Nature 408: 1008–1012
Rollinger JM, Hornick A, Langer T, Stuppner H, Prast H (2004) Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. J Med Chem 47: 6248–6254
Langer T, Krovat EM (2003) Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr Opin Drug Discov Dev 6: 370–376
Schuster D, Maurer E, Laggner C, Nashev L, Wilckens T, Langer T, Odermatt A (2006) The discovery of new 11gb-hydroxysteroid dehydrogenase Type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J Med Chem 49: 3454–3466
Schuster D, Laggner C, Steindl TM, Palusczak A, Hartmann RW, Langer T (2006) Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. J Chem Inf Model 46: 1301–1311
Kurogi Y, Güner OF (2001) Pharmacophore modeling and three-dimensional database searching for drug design using Catalyst. Curr Med Chem 8: 1035–1055
Güner O, Clement O, Kurogi Y (2004) Pharmacophore modeling and three dimensional database searching for drug design using CATALYST: Recent advances. Curr Med Chem 11: 763–771
Füllbeck M, Huang X, Dumdey R, Frommel C, Dubiel W, Preissner R (2005) Novel curcumin-and emodin-related compounds identified by in silico 2D/3D conformer screening induce apoptosis in tumor cells. BMC Cancer 5: 97
Laggner C, Schieferer C, Fiechtner B, Poles G, Hoffmann RD, Glossmann H, Langer T, Moebius F (2005) Feature based pharmacophore models for sigma1 receptor, ERG2 and EBP. J Med Chem 48: 4754–4764
Zupan J, Gasteiger J (1999) Neural networks in chemistry and drug design, 2nd Ed. Wiley-VCH, Weinheim
Wagner S, Hofmann A, Siedle B, Terfloth L, Merfort I, Gasteiger J (2006) Development of a structural model for NF-κB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem 49: 2241–2252
Sangma C, Chuakheaw D, Jongkon N, Saenbandit K, Nunrium P, Uthayopas P, Hannongbua S (2005) Virtual screening for anti-HIV-1 RT and anti-HIV-1 PR inhibitors from the Thai Medicinal Plants Database: A combined docking with neural networks approach. Comb Chem HTS 8: 417–429
Cherkasov A, Shi Z, Fallahi M, Hammond GL (2005) Successful in silico discovery of novel nonsteroidal ligands for human sex hormone binding globulin. J Med Chem 48: 3203–3213
Svetnik V, Liaw A, Tong D, Culberson C, Sheridan RP, Feuston BP (2003) Random Forest: a classification and regression tool for compound classification and QSAR Modeling. J Chem Inf Comput Sci 43: 1947–1958
Ehrman TM, Barlow DJ, Hylands PJ (2007) Virtual screening of Chinese herbs with random forest. J Chem Inf Model ASAP 10.1021/ci600289v
Kirchmair J, Laggner C, Wolber G, Langer T (2005) Comparative analysis of protein-bound ligand conformations with respect to catalyst’s conformational space subsampling algorithms. J Chem Inf Model 45: 422–430
Poroikov VV, Filimonov DM, Ihlenfeldt WD, Gloriozova TA, Lagunin AA, Borodina YV, Stepanchikova AV, Nicklaus MC (2003) PASS Biological activity predictions in the enhanced open NCI database browser. J Chem Inf Comput Sci 43: 228–236
Lu A, Liu B, Liu H, Zhou J, Xie G (2004) A traditional Chinese medicine plant-compound database aid its application for searching. Int Electron J Mol Des 3: 672–683
Füllbeck M, Michalsky E, Dunkel M, Preissner R (2006) Natural products: sources and databases. Nat Prod Rep 23: 347–356
Dunkel M, Füllbeck M, Neumann S, Preissner R (2006) SuperNatural: a searchable database of available natural compounds. Nucleic Acid Res 34: D678–683
Lei J, Zhou J (2002) A marine natural product database. J Chem Inf Comp Sci 42: 742–748
Rollinger JM, Haupt S, Stuppner H, Langer T (2004) Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example. J Chem Inf Comp Sci 44: 480–488
Bernard P, Berton JY, Chrétien JR (1999) Computer-aided molecular selection and design of natural bioactive molecules. Curr Opin Drug Disc Dev 2: 213–223
Ehrman TM, Barlow DJ, Hylands PJ (2007) Phytochemical databases of Chinese herbal constituents and bioactive plant compounds with known target specifities. J Chem Inf Model ASAP 10.1021/ci600288m
Rollinger JM, Langer T, Stuppner H (2006) Strategies for efficient lead structure discovery from natural products. Curr Med Chem 13: 1491–1507
Rollinger JM, Langer T, Stuppner H (2006) Integrated in silico tools to exploit the natural products’ bioactivity. Planta Med 72: 671–678
Van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nature Rev Drug Disc 2: 192–204
Rollinger JM, Bodensieck A, Seger C, Ellmerer EP, Bauer R, Langer T, Stuppner H (2005) Discovering COX-inhibiting constituents of Morus root bark: Activity-guided versus computer-aided methods. Planta Med 71: 399–405
Bernard P, Scior T, Didier B, Hibert M, Berthon JY (2001) Ethnopharmacology and bioinformatic combination for leads discovery: application to phospholipase A2 inhibitors. Phytochemistry 58: 865–874
Van de Waterbeemd H (2005) Which in vitro screens guide the prediction of oral absorption and volume of distribution? Bas Clin Pharmacol Toxicol 96: 162–166
Rollinger JM, Mock P, Zidorn C, Ellmerer EP, Langer T, Stuppner H (2005) Application of the in combo screening approach for the discovery of non-alkaloid acetylcholinesterase inhibitors from Cichorium intybus. Curr Drug Discov Techn 2:185–193; Erratum (2006) 3: 89
Bajorath J (2002) Virtual screening in drug discovery: methods, expectations and reality. Curr Drug Disc March: 24–28
Bajorath J (2002) Integration of virtual and high-throughput screening. Nature Rev Drug Discovery 1 Nov: 882–894
Chimenti F, Cottiglia F, Bonsignore L, Casu L, Casu M, Floris C, Secci D, Bolasco A, Cimenti P, Granese A et al (2006) Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: extraction, biological analysis, and computational study. J Nat Prod 69: 945–949
Rollinger JM, Schuster D, Baier E, Ellmerer EP, Langer T, Stuppner H (2006) Taspine: Bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana. J Nat Prod 69: 1341–1346
Rognan D (2006) In silico screening of the protein structure repertoire and of protein families. Chemogenomics 109–131
Paul N, Kellenberger E, Bret G, Mueller P, Rognan D (2004) Recovering the true targets of specific ligands by virtual screening of the Protein Data Bank. Proteins 54: 671–680
Nettles JH, Jenkins JL, Bender A, Deng Z, Davies JW, Glick M (2006) Bridging chemical and biological space: “target fishing” using 2D and 3D molecular descriptors. J Med Chem 49: 6802–6810
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Birkhäuser Verlag, Basel (Switzerland)
About this chapter
Cite this chapter
Rollinger, J.M., Stuppner, H., Langer, T. (2008). Virtual screening for the discovery of bioactive natural products. In: Petersen, F., Amstutz, R. (eds) Natural Compounds as Drugs Volume I. Progress in Drug Research, vol 65. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8117-2_6
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8117-2_6
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8098-4
Online ISBN: 978-3-7643-8117-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)